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First recognized in the United States in 1986,
the human ehrlichioses are considered emerging
zoonotic diseases. Two etiologically and epide-
miologically distinct forms of illness are
recognized: human monocytic ehrlichiosis (HME),
caused by Ehrlichia chaffeensis (1), and human
granulocytic ehrlichiosis (HGE), caused by an
agent similar or identical to the veterinary
pathogens E. equi and E. phagocytophila (2). A
third species, E. ewingii, can also cause human
illness (3). The bacteria that cause ehrlichiosis
are transmitted to humans through the bite of
infected ticks, which acquire the agents after
feeding on infected animal reservoirs.
During infection, ehrlichiae form distinctive
membrane-bound, intracytoplasmic bacterial
aggregates (morulae) in white blood cells. HME
is characterized by morulae in monocytes, HGE
by morulae in granulocytes. Clinically, HME and
HGE are nearly indistinguishable and are
characterized by one or more of the following
symptoms: fever, headache, myalgia, thrombocy-
topenia, leukopenia, and elevated liver enzyme
levels (4-8). A rash occurs in approximately one
third of patients with HME (8) but is less
common in patients with HGE (4,9). Most cases
of ehrlichiosis are characterized by mild illness.
However, complications such as adult respira-
tory distress syndrome, renal failure, neurologic
disorders, and disseminated intravascular co-
agulation can occur (6,10). Case-fatality ratios
are as high as 5% for HME and 10% for HGE (10),
although more serious cases are probably
overrepresented in these estimates. Other
studies have reported case-fatality ratios of <5%
for these diseases (4,7).
HME and HGE are most often diagnosed by
indirect immunofluorescence assay (IFA), al-
though polymerase chain reaction (PCR) assays
are increasingly used (11). A confirmed case is
defined as a fourfold change in antibody titer by
IFA in acute- and convalescent-phase serum
samples, PCR amplification of ehrlichial DNA
from a clinical sample, or detection of
intraleukocytic morulae and a single IFA titer of
≥ 64. A probable case is defined as a single IFA
titer of ≥ 64 or the presence of morulae within
infected leukocytes. Laboratory data are only
used to support clinical suspicion; the designa-
tion of a confirmed or probable case of
ehrlichiosis is interpreted in the context of
compatible illness (11).
The public health importance of the
ehrlichioses has not been well defined, largely
because these diseases are newly recognized.
Because ehrlichiae are present in blood,
concerns have been raised about the risk for
perinatal and blood-transfusion transmission
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The emerging tick-borne zoonoses human monocytic ehrlichiosis (HME) and
human granulocytic ehrlichiosis (HGE) are underreported in the United States. From
1986 through 1997, 1,223 cases (742 HME, 449 HGE, and 32 not ascribed to a specific
ehrlichial agent) were reported by state health departments.  HME was most  commonly
reported from southeastern and southcentral states, while HGE was most often reported
from northeastern and upper midwestern states. The annual number of reported cases
increased sharply, from 69 in 1994 to 364 in 1997, coincident with an increase in the
number of states making these conditions notifiable. From 1986 through 1997, 827
probable and confirmed cases were diagnosed by serologic testing at the Centers for
Disease Control and Prevention, although how many of these cases were also reported
by states is not known. Improved national surveillance would provide a better
assessment of the public health importance of ehrlichiosis.
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Table. Average annual ehrlichiosis incidence (per one
million population) for reporting statesa on the basis of
1995 census data (18)
Incidence
  Human    Human
 monocytic granulocytic
State ehrlichiosis  ehrlichiosis
Arkansas 5.53  0
Arizona 0.12  0
California 0.02  0.03
Connecticut 0.92 15.90
Florida 0.74  0
Illinois 0.11  0.03
Indiana 0.91  0
Kentucky 0.40  0
Maine 0  0
Minnesota 0.22  3.90
Missouri 3.05  0
North Carolina 4.72  0.05
New Hampshire 0  0
New Jersey 1.47  0.17
New York 0.38  2.68
Oklahoma 2.90  0
Pennsylvania 0.01  0.03
Rhode Island 0  0.67
Texas 0.20  0
Virginia 0.68  0
Wisconsin 0  8.79
aIncludes states that consider ehrlichiosis notifiable, as well
as five states where data are routinely collected. Michigan,
South Carolina, and Tennessee did not differentiate between
cases of human monocytic ehrlichiosis and human granulo-
cytic ehrlichiosis and are not included in this table.
(12,13). Ehrlichiae are susceptible to tetracy-
clines, so rapid and effective treatment is possible
(8). However, the nonspecific signs and symptoms
of these diseases may interfere with timely
clinical diagnosis. Ehrlichial infections can be
life-threatening. Raising disease awareness and
educating physicians and the public about clinical
manifestations and proper treatment are indicated.
A national ehrlichiosis surveillance program
does not exist, so national incidence rates have
not been determined because of wide variability
in state surveillance activities. The Council of
State and Territorial Epidemiologists recom-
mended that human ehrlichiosis be made
nationally notifiable in 1998, but many states do
not have a system for surveillance and do not test
for ehrlichiosis in state diagnostic laboratories.
We summarize the scope of state-supported
surveillance efforts and present data on
ehrlichiosis cases reported to state health
departments from 1986 through 1997. In
addition, we include data on ehrlichiosis cases
diagnosed by serologic testing at the Centers for
Disease Control and Prevention (CDC).
Reported Ehrlichiosis Cases in the United
States
From 1986 through 1997, 1,223 ehrlichiosis
cases were reported by 30 state health
departments in the United States. Data were
reported from 19 states that considered
ehrlichiosis notifiable as of August 1998, five
that routinely collected information on cases,
and six that occasionally received reports of
ehrlichiosis cases (Appendix I) (14-17). For states
where ehrlichiosis was not notifiable, the
designation routine reporting versus occasional
reporting was based on the completeness of data
provided. Because some states did not differenti-
ate between probable and confirmed cases in
their records, both categories were considered
cases for the purposes of this report. Of the 1,223
reported ehrlichiosis cases, 742 (60.7%) were
categorized as HME, 449 (36.7%) as HGE, and 32
(2.6%) as not ascribed to a specific ehrlichial
agent. Using data from 20 states that reported
information on deaths, we found case-fatality
ratios of 2.7% (8 of 299) for HME and 0.7% (3 of
448) for HGE.
HME and HGE Incidence
Data provided through 1997 were used to
calculate state-specific average annual incidence
rates for 16 of the 19 states that considered
ehrlichiosis notifiable and the five states that
routinely collected surveillance data (Table).
Although Missouri, South Carolina, and Tennes-
see considered ehrlichiosis notifiable, average
annual incidence rates could not be calculated
because these states did not differentiate
between HME and HGE. Average annual
incidence per one million population was
calculated by dividing the number of reported
cases by the number of years a state collected
data (Table). When possible, average annual
incidence by county was determined for HME
and HGE (Figures 1-2) (15,17).
Most HME cases were reported from the
southeastern and southcentral areas of the United
States (Table, Figure 1). The highest reported
average annual incidence rates of HME were in
Arkansas (5.53 per million), North Carolina (4.72
per million), Missouri (3.05 per million), and
Oklahoma (2.90 per million). In contrast, the
highest reported average annual incidence rates
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Figure 1. Average annual incidence of reported
human monocytic ehrlichiosis (HME) by county,
using 1995 population census data (29). Includes
states that consider ehrlichiosis notifiable, as well as
states that routinely collect information on ehrlichiosis
cases. Michigan, South Carolina, and Tennessee are
not included because cases of HME and human
granulocytic ehrlichiosis were not distinguished by
the state health departments. County-specific
incidence could not be calculated for North Carolina
or Pennsylvania because county of occurrence was not
provided by the state health departments.
Figure 2. Average annual incidence of reported
human granulocytic ehrlichiosis (HGE) by county,
using 1995 population census data (29). Includes
states that consider ehrlichiosis notifiable, as well as
states that routinely collect information on ehrlichiosis
cases. Michigan, South Carolina, and Tennessee are
not included because cases of human monocytic
ehrlichiosis and HGE were not distinguished by the
state health departments. County-specific incidence
could not be calculated for North Carolina or
Pennsylvania because county of occurrence was not
provided by the state health departments.
Figure 3. Reported cases of human monocytic
ehrlichiosis (HME) and human granulocytic ehrlichiosis
(HGE) in the United States, 1986-1997 (includes cases
from states that consider ehrlichiosis notifiable, as well
as states that routinely collect information). Because
yearly summaries of reported cases were not available
for Missouri, data from this state are not included. The
number of states where ehrlichiosis was notifiable
increased from 7 in 1994 to 17 in 1997.
of HGE were in the northeastern and upper
midwestern areas of the United States
Connecticut (15.90 per million), Wisconsin (8.79
per million), Minnesota (3.90 per million), and New
York (2.68 per million) (Figure 2). The county
reporting the highest average annual incidence
of HME was Searcy, Arkansas (64.80 per million),
and the county with the highest annual incidence
of HGE was Jackson, Wisconsin (521.68 per million).
These incidence rates follow the expected
geographic distribution of tick vectors for each
type of ehrlichiosis. E. chaffeensis is primarily
transmitted by the lone star tick (Amblyomma
americanum), which is common in the southeast-
ern United States (19). The black-legged tick
(Ixodes scapularis) transmits the causative agent
of HGE in the northeastern United States (20,21)
and the western black-legged tick (I. pacificus) in
the western coastal United States (22).
Reporting Trends
The annual number of ehrlichiosis cases
reported by the state health departments was
calculated with data from 18 states that
considered ehrlichiosis notifiable as of August
1998 (yearly summaries were not available for
Missouri) and the five additional states that
routinely collected information on ehrlichiosis
cases (Figure 3). The annual number of reported
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Figure 4. Human monocytic ehrlichiosis cases
diagnosed by indirect immunofluorescence assay
(IFA), Centers for Disease Control and Prevention,
1986 to 1997.
Figure 5. Human granulocytic ehrlichiosis cases
diagnosed by indirect immunofluorescence assay
(IFA), Centers for Disease Control and Prevention,
1995 to 1997.
ehrlichiosis cases increased sharply, from 69 in
1994 to 364 in 1997. This increase may be
explained by the addition of ehrlichiosis as a
notifiable disease in 10 states during this same 4-
year interval, the discovery of HGE in 1994,
increased availability of diagnostic tests, and
increased awareness of ehrlichiosis.
Ehrlichioses Cases Diagnosed at CDC
At CDC, antigen from E. chaffeensis,
Arkansas strain, is used to diagnose HME by
IFA. Before E. chaffeensis was isolated in 1991,
E. canis was used as a surrogate antigen (23).
During  1995 to 1996, antigen from E. equi
obtained from infected horse neutrophils was
used, but cases submitted to CDC after 1996
were diagnosed by IFA using cell culture
derived antigen from the HGE agent (24).
Antibody from patients with ehrlichial infection
may cross-react with both E. chaffeensis and the
HGE agent (24,25). For patients with significant
antibody titers to both Ehrlichia species, the
causative agent is assumed to be the one with a
fourfold or greater change in antibody titer
between paired serum samples. If both agents
show a fourfold difference, the one with the
highest titer is considered the causative agent. If
neither shows a fourfold difference, the
causative agent is usually not ascribed to a
specific ehrlichial species (25).
Of 827 probable and confirmed ehrlichiosis
cases diagnosed by IFA from serum or plasma
specimens submitted to CDC through the end of
1997, 754 were HME, 44 were HGE, and 29 could
not be differentiated because of antibody cross-
reactivity. The geographic distribution was
widespread (Figures 4, 5), and cases of
ehrlichiosis were diagnosed from every state
except North Dakota and South Dakota
(Appendix 2). Imported disease acquired by
travel to disease-endemic areas may explain
cases reported from states without the recog-
nized tick vectors, including Hawaii and Alaska.
Because information about clinical manifesta-
tions was not always provided with specimens,
whether all cases had compatible clinical illness
is unknown. Of 754 HME cases, 423 (56.1%) were
classified as probable and 331 (43.9%) as
confirmed on the basis of serologic criteria
established by CSTE and CDC (11). In contrast,
of 44 HGE cases, 39 (88.6%) were classified as
probable and 5 (11.4%) as confirmed.
Conclusions
Although a few state health departments
have published information on local ehrlichiosis
surveillance (14-17,26-28), comprehensive na-
tional surveillance data had not been collected
until this review. This review further defines the
public health problem posed by the ehrlichioses
in the United States. These diseases have
incidence rates comparable with or exceeding
those of Rocky Mountain spotted fever in some
states (29).
These state-reported data have several
limitations. State health departments provided
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information on ehrlichiosis cases in different
ways. For example, some states provided only
data compiled after ehrlichiosis became notifi-
able, while others provided information as far
back as data were available. The ehrlichiosis
cases in this article represent a compilation of
existing (albeit incomplete) surveillance datasets
and probably underestimate the true prevalence
of the disease in the United States. Moreover, the
accuracy of HME and HGE case-fatality ratios
presented here is uncertain. The number of
deaths may be underreported because diagnosis
of ehrlichiosis requires laboratory confirmation.
However, serious or complicated cases, more
likely to end in death, are more likely to be
investigated and reported to state health
departments. The case-fatality ratios described
in this article are compatible with findings from
other studies (4,7). Finally, the state-reported
data include some cases from areas where
ehrlichiosis is not commonly diagnosed. For
example, a single case of HME was reported from
Arizona, although the recognized distribution of
the lone star tick does not include this state.
Ehrlichiosis cases are usually reported from the
patients county and state of residence at the
time of diagnosis; however, ehrlichiosis may be
acquired during travel to an area with Ehrlichia-
infected ticks. Imported cases of ehrlichiosis in
states where the disease is not common or tick
vectors are absent underscores the need to
consider this diagnosis even in areas of low risk.
Diagnostic serologic testing has been offered
at CDC since 1986 for HME, and since 1995 for
HGE. Records show that from 1986 through 1997
more than 800 ehrlichiosis cases were diagnosed
from 48 states. This finding contrasts sharply
with state-reported surveillance data, which
identified specific geographic regions where
ehrlichiosis was most likely to occur.
The number of cases diagnosed at CDC from
each state may not accurately reflect expected
regional incidence patterns; for example, states
with public health laboratories that offer in-
house diagnostic tests or states that frequently
use commercial laboratories may be less likely to
submit samples to CDC for testing. Some cases of
ehrlichiosis diagnosed at CDC may also have
been reported by state surveillance systems;
these reporting systems cannot be regarded as
mutually exclusive. The numbers of serologically
diagnosed cases of ehrlichiosis reported here
may differ from numbers published in other CDC
reports because other reports include samples
obtained for specific studies (7), whereas most of
the cases in this report were submitted for
routine diagnostic tests.
As of August 1998, only 19 states considered
ehrlichiosis notifiable, and fewer than one fourth
of state health departments offered in-house
diagnostic assays for HME or HGE. Average
annual incidence rates, an important indicator of
disease prevalence, could be calculated for only
21 states. These data underscore the need for
better nationwide surveillance of ehrlichiosis.
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Appendix I: Ehrlichiosis surveillance by state health departments as of August 1998 and total number of cases reported through 1997.
Human Human
Laboratory monocytic granulocytic Ehrlichial
First year Tests ehrlichiosis ehrlichiosis agent not Total
State reportable offered cases cases specified cases
Alabama Not reportable None available     --     --   --       --
Alaska Not reportable None available     --     --   --       --
Arizona 1997 None available     1     0   0        1
Arkansas 1993 None available   55     0   0      55
California 1996 IFA for both; PCR for both     2     3   0        5
Colorado Not reportablea None available     --     --   3        3
Connecticut 1995 IFA for both; PCR for both     9 156   9    174
Delaware Not reportable None available     --     --   --       --
District of Columbia Not reportable None available     --     --   --       --
Florida 1996 IFA for HME only   21     0   0      21
Georgia Not reportable None available     --     --   --       --
Hawaii Not reportable None available     --     --   --       --
Idaho Not reportable None available     --     --   --       --
Illinois Not reportableb None available     5     1   2       8
Indiana Not reportableb IFA for HME only   21     0   0      21
Iowa Not reportable IFA for both; PCR for both     --     --   --       --
Kansas Not reportable None available     --     --   --       --
Kentucky 1989 None available   14     0   0      14
Louisiana Not reportablea None available     --     --   1        1
Maine 1996 None available     0     0   0        0
Maryland Not reportablea IFA for both     6     0   1        7
Massachusetts Not reportablea None available     0     5   0        5
Michigan 1993 None available     --     --   2        2
Minnesota 1996 None available     2   36   0      38
Mississippi Not reportablea None available     --     --   1        1
Missouri Reportable, date None available 162     0   0    162
  unknown
Montana Not reportable None available     --     --   --       --
Nebraska Not reportable None available     --     --   --       --
Nevada Not reportable None available     --     --   --       --
New Hampshire 1996 None available     0     0   0       0
New Jersey 1995 IFA for both; PCR for both   35     4   0      39
New Mexico Not reportablea None available     1     0   0        1
New York 1996 IFA for both; PCR for both   28 195   0    223
North Carolina 1998 IFA for HME only  204     1   0    205
North Dakota Not reportable None available    --     --   --       --
Ohio Not reportable None available    --     --   --       --
Oklahoma Not reportableb None available   76     0   0      76
Oregon Not reportable None available    --     --   --       --
Pennsylvania 1992 None available     1     1   1        3
Rhode Island 1996 None available     0     2   0        2
South Carolina 1990 None available    --     --   5        5
South Dakota Not reportable None available    --     --   --       --
Tennessee 1996 IFA for HME only    --     --   7        7
Texas 1996 IFA for HME only;   45     0   0      45
  PCR for both
Utah Not reportable None available    --     --   --       --
Vermont Not reportable None available    --     --   --       --
Virginia Not reportableb None available   54     0   0      54
Washington Not reportable None available    --     --   --       --
West Virginia Not reportable None available    --     --   --       --
Wisconsin Not reportableb IFA for both; PCR     0   45   0      45
  for HGE only
Wyoming Not reportable None available    --     --   --       --
Total n/a n/a 742 449 32 1,223
aOccasionally received reports of ehrlichiosis cases.
bRoutinely collected information on ehrlichiosis cases.
HME, human monocytic ehrlichiosis; HGE, human granulocytic ehrlichiosis; -, not reported by states; IFA, indirect immunofluorescence assay;
PCR, polymerase chain reaction; n/a, not applicable.
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Appendix II: Probable and confirmed ehrlichiosis cases diagnosed by indirect immunfluorescence assay (IFA), Centers for Disease
Control and Prevention, 1986 through 1997.
Human monocytic Human granulocytic Ehrlichial agent
 ehrlichiosis ehrlichiosis not determineda Total
State Probb     Confc      Total Probb   Confc     Total Probb    Confc     Total cases
Alabama     8     4   12   0 0   0   0   1   1   13
Alaska     2     0     2   0 0   0   0   0   0     2
Arizona     0     1     1   0 0   0   0   0   0     1
Arkansas   32   20   52   8 0   8   1   1   2   62
California   15     9   24   0 0   0   0   0   0   24
Colorado     6     1     7   0 0   0   0   0   0     7
Connecticut     9     4   13   0 1   1   0   0   0   14
Delaware     1     1     2   0 0   0   0   0   0     2
District of Columbia     4     8   12   0 0   0   1   0   1   13
Florida   15     7   22   0 1   1   2   1   3   26
Georgia   30   25   55   1 0   1   1   0   1   57
Hawaii     2     4     6   0 0   0   0   0   0     6
Idaho     3     0     3   1 0   1   0   0   0     4
Illinois     3     5     8   0 0   0   0   0   0     8
Indiana     9     0     9   0 0   0   0   0   0     9
Iowa   19     5   24   8 0   8   2   0   2   34
Kansas     1     2     3   0 0   0   0   0   0     3
Kentucky     5     2     7   0 0   0   0   0   0     7
Louisiana     5     2     7   0 0   0   0   0   0     7
Maine     2     1     3   0 0   0   0   0   0     3
Maryland   18     7   25   0 0   0   1   1   2   27
Massachusetts   10     3   13   5 1   6   1   1   2   21
Michigan     4     2     6   0 0   0   0   0   0     6
Minnesota     5     3     8   0 0   0   0   0   0     8
Mississippi     0     2     2   0 0   0   0   0   0     2
Missouri   61   84 145   0 1   1   2   2   4 150
Montana     2     0     2   1 0   1   0   0   0     3
Nebraska   17     1   18   1 0   1   0   1   1   20
Nevada     0     1     1   1 0   1   0   0   0     2
New Hampshire     1     0     1   0 0   0   0   0   0     1
New Jersey     4     9   13   1 0   1   0   0   0   14
New Mexico     1     0     1   0 0   0   0   0   0     1
New York   13     3   16   2 0   2   0   0   0   18
North Carolina   28     5   33   0 0   0   1   1   2   35
North Dakota     0     0     0   0 0   0   0   0   0     0
Ohio     4     0     4   0 0   0   0   0   0     4
Oklahoma     4     7   11   3 0   3   0   1   1   15
Oregon     0     1     1   0 0   0   0   0   0     1
Pennsylvania     2     6     8   0 0   0   0   0   0     8
Rhode Island     2     0     2   0 0   0   0   0   0     2
South Carolina     4     4     8   0 0   0   0   0   0     8
South Dakota     0     0     0   0 0   0   0   0   0     0
Tennessee   15   22   37   4 0   4   2   0   2   43
Texas   22   31   53   0 0   0   0   0   0   53
Utah     0     1     1   0 0   0   0   0   0     1
Vermont     2     0     2   0 0   0   0   0   2     4
Virginia   17   29   46   1 0   1   2   0   2   49
Washington   13     6   19   0 0   0   0   0   0   19
West Virginia     0     0     0   0 0   0   0   1   1     1
Wisconsin     3     1     4   2 1   3   1   1   2     9
Wyoming     0     2     2   0 0   0   0   0   0     2
Total 423 331 754 39 5 44 17 12 29 827
aIncludes cases that could not be ascribed to a specific ehrlichial agent because of antibody cross-reactivity.
bProbable case (single antibody titer of ≥ 64 by IFA).
cConfirmed case (fourfold change in antibody titer in paired serum samples by IFA).
